Drug profile · INN
gemfibrozil
LOPID
- US status
- approved
- Patents linked
- 6
- News articles
- 0
Quick answer
gemfibrozil (LOPID) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Related patents
Search patents →-
US 11642335
Chemical synthesis of clopidogrel active metabolites and disulfide conjugate prodrugs
granted -
US 9889125
Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
granted -
US 9233103
Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
granted -
US 7259261
Racemization and enantiomer separation of clopidogrel
granted -
US 6800759
Racemization and enantiomer separation of clopidogrel
expired -
US 6737411
Racemization and enantiomer separation of clopidogrel
expired
Frequently asked questions
What is gemfibrozil?
gemfibrozil (LOPID) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for gemfibrozil?
LOPID is a marketed brand name for gemfibrozil. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of gemfibrozil?
gemfibrozil has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.